Answer
Patients with von Willebrand disease, especially type 3, may develop neutralising antibodies to von Willebrand factor during Willfact treatment; testing is indicated if expected VWF:RCo plasma activity is not attained or bleeding is not controlled with an appropriate dose.
Sources for this answer
- Willfact 1000 IU Powder and solvent for solution for injectionLFB Biopharmaceuticals Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 5Document updated
Sources checked